Ryvu Therapeutics stock exits S&P Global BMI Index

Published on 10/06/2026 at 10:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ryvu Therapeutics stock costs EUR 3.60 on October 6, 2026 after EUR 3.61. Half-year revenue fell to PLN 38.7 million from PLN 42.4 million.

Ryvu Therapeutics, PLSELVT00013, Illustration mit AI erstellt.

Ryvu Therapeutics (PLSELVT00013) was trading at EUR 3.60 at Lang & Schwarz on October 6, 2026 at 10:04 a.m. CEST, down 0.28 percent versus the prior close of EUR 3.61. The biotechnology company was removed from the S&P Global BMI Index on September 20, 2026, according to MarketScreener.

Index exit meets clinical progress

The index change adds a market-structure overhang to a pipeline story that is still centered on oncology. Ryvu said its lead program, romacyclib, entered an expansion cohort of the Phase II RIVER-81 study on August 26, 2026, targeting relapsed or refractory acute myeloid leukemia.

In its first-half update dated September 17, 2026, Strefa Inwestorow reported that the company had presented a 43 percent complete response or complete response with incomplete blood count recovery rate in one RIVER-81 dosing cohort, based on 3 of 7 patients. The same update said the company launched Keelira on August 18, 2026, adding an early clinical development services business alongside its proprietary pipeline.

Revenue fell while losses narrowed

Ryvu generated PLN 38.7 million of operating revenue in the first half of 2026, compared with PLN 42.4 million in the first half of 2025. Operating costs excluding non-cash incentive and NodThera valuation items declined to PLN 67.6 million from PLN 95.5 million, while adjusted net loss attributable to ordinary shareholders narrowed to PLN 25.4 million from PLN 57.1 million, according to Strefa Inwestorow.

The second-quarter comparison was less favorable against expectations. Bankier.pl reported second-quarter revenue of PLN 17.0 million versus a PLN 21.2 million consensus, a shortfall of 19.8 percent. The quarter also produced an EBITDA loss of PLN 14.7 million against a PLN 10.6 million consensus loss.

Ryvu stock remains below its yearly high

On the primary GPW listing, RVU.WA was quoted at PLN 15.78 at 9:49 a.m. CEST on October 6, 2026. The finance quote showed a PLN 13.64 to PLN 31.90 52-week range and market capitalization of PLN 364.8 million, placing the shares below the yearly high while the euro reference quote remained near its prior close.

Liquidity is another measurable issue for the clinical-stage model. Ryvu reported cash, equivalents, bonds and investment funds of PLN 74.5 million on June 30, 2026, versus PLN 107.7 million on December 31, 2025, while recommended grant support for PANACEA-NOVO and DUALIS totaled PLN 128.9 million.